Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats

Aly Abdelrahman, Yousuf Al Suleimani, Mohammed Ashique, Priyadarsini Manoj, Badreldin Ali

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fructose administration can induce hypertension, insulin resistance and hypertriglyceridemia. Here, we investigated the possible protective effect of infliximab (IFX), a tumor necrosis factor alpha (TNF-α) inhibitor, or tocilizumab (TOC), an interleukin-6 (IL6) inhibitor, on fructose-induced increase in blood pressure, insulin resistance and hyperlipidemia in rats. The animals were fed a 60% fructose diet in the absence or presence of IFX (5 mg/kg, i.p., once weekly) or TOC (8 mg/kg, i.p., once every two weeks). Fructose significantly increased blood pressure, heart rate and homeostatic model assessment of insulin resistance (HOMA-IR). Fructose also significantly raised the concentrations of fasting plasma insulin, triglycerides, total cholesterol, uric acid, tumor necrosis factor–alpha (TNF-α), interleukin 6 (IL-6), malondialdhyde (MDA) and nitric oxide. Fructose also significantly decreased plasma superoxide dismutase (SOD) and catalase activities. In addition, fructose significantly increased aortic endothelin and nitric oxide concentrations. Both IFX and TOC attenuated the fructose-induced increase in blood pressure, insulin resistance, and the concentrations of uric acid, MDA and IL-6. TOC significantly reduced fructose-induced increase in triglycerides and cholesterol. In addition, IFX increased plasma SOD and catalase activities. Our results showed that both IFX and TOC were partially successful in reversing fructose – induced changes.

Original languageEnglish
Pages (from-to)182-186
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume105
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Hyperinsulinism
Fructose
Hypertension
Insulin Resistance
Interleukin-6
Blood Pressure
Uric Acid
Catalase
Superoxide Dismutase
Nitric Oxide
Triglycerides
Cholesterol
Infliximab
tocilizumab
Hypertriglyceridemia
Endothelins
Hyperlipidemias
Fasting
Necrosis
Tumor Necrosis Factor-alpha

Keywords

  • Blood pressure
  • Fructose
  • Infliximab
  • Insulin resistance
  • Tocilizumab

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats. / Abdelrahman, Aly; Al Suleimani, Yousuf; Ashique, Mohammed; Manoj, Priyadarsini; Ali, Badreldin.

In: Biomedicine and Pharmacotherapy, Vol. 105, 01.09.2018, p. 182-186.

Research output: Contribution to journalArticle

@article{4607d471b6b742e19619186a3f6b88f4,
title = "Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats",
abstract = "Fructose administration can induce hypertension, insulin resistance and hypertriglyceridemia. Here, we investigated the possible protective effect of infliximab (IFX), a tumor necrosis factor alpha (TNF-α) inhibitor, or tocilizumab (TOC), an interleukin-6 (IL6) inhibitor, on fructose-induced increase in blood pressure, insulin resistance and hyperlipidemia in rats. The animals were fed a 60{\%} fructose diet in the absence or presence of IFX (5 mg/kg, i.p., once weekly) or TOC (8 mg/kg, i.p., once every two weeks). Fructose significantly increased blood pressure, heart rate and homeostatic model assessment of insulin resistance (HOMA-IR). Fructose also significantly raised the concentrations of fasting plasma insulin, triglycerides, total cholesterol, uric acid, tumor necrosis factor–alpha (TNF-α), interleukin 6 (IL-6), malondialdhyde (MDA) and nitric oxide. Fructose also significantly decreased plasma superoxide dismutase (SOD) and catalase activities. In addition, fructose significantly increased aortic endothelin and nitric oxide concentrations. Both IFX and TOC attenuated the fructose-induced increase in blood pressure, insulin resistance, and the concentrations of uric acid, MDA and IL-6. TOC significantly reduced fructose-induced increase in triglycerides and cholesterol. In addition, IFX increased plasma SOD and catalase activities. Our results showed that both IFX and TOC were partially successful in reversing fructose – induced changes.",
keywords = "Blood pressure, Fructose, Infliximab, Insulin resistance, Tocilizumab",
author = "Aly Abdelrahman and {Al Suleimani}, Yousuf and Mohammed Ashique and Priyadarsini Manoj and Badreldin Ali",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.biopha.2018.05.118",
language = "English",
volume = "105",
pages = "182--186",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats

AU - Abdelrahman, Aly

AU - Al Suleimani, Yousuf

AU - Ashique, Mohammed

AU - Manoj, Priyadarsini

AU - Ali, Badreldin

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Fructose administration can induce hypertension, insulin resistance and hypertriglyceridemia. Here, we investigated the possible protective effect of infliximab (IFX), a tumor necrosis factor alpha (TNF-α) inhibitor, or tocilizumab (TOC), an interleukin-6 (IL6) inhibitor, on fructose-induced increase in blood pressure, insulin resistance and hyperlipidemia in rats. The animals were fed a 60% fructose diet in the absence or presence of IFX (5 mg/kg, i.p., once weekly) or TOC (8 mg/kg, i.p., once every two weeks). Fructose significantly increased blood pressure, heart rate and homeostatic model assessment of insulin resistance (HOMA-IR). Fructose also significantly raised the concentrations of fasting plasma insulin, triglycerides, total cholesterol, uric acid, tumor necrosis factor–alpha (TNF-α), interleukin 6 (IL-6), malondialdhyde (MDA) and nitric oxide. Fructose also significantly decreased plasma superoxide dismutase (SOD) and catalase activities. In addition, fructose significantly increased aortic endothelin and nitric oxide concentrations. Both IFX and TOC attenuated the fructose-induced increase in blood pressure, insulin resistance, and the concentrations of uric acid, MDA and IL-6. TOC significantly reduced fructose-induced increase in triglycerides and cholesterol. In addition, IFX increased plasma SOD and catalase activities. Our results showed that both IFX and TOC were partially successful in reversing fructose – induced changes.

AB - Fructose administration can induce hypertension, insulin resistance and hypertriglyceridemia. Here, we investigated the possible protective effect of infliximab (IFX), a tumor necrosis factor alpha (TNF-α) inhibitor, or tocilizumab (TOC), an interleukin-6 (IL6) inhibitor, on fructose-induced increase in blood pressure, insulin resistance and hyperlipidemia in rats. The animals were fed a 60% fructose diet in the absence or presence of IFX (5 mg/kg, i.p., once weekly) or TOC (8 mg/kg, i.p., once every two weeks). Fructose significantly increased blood pressure, heart rate and homeostatic model assessment of insulin resistance (HOMA-IR). Fructose also significantly raised the concentrations of fasting plasma insulin, triglycerides, total cholesterol, uric acid, tumor necrosis factor–alpha (TNF-α), interleukin 6 (IL-6), malondialdhyde (MDA) and nitric oxide. Fructose also significantly decreased plasma superoxide dismutase (SOD) and catalase activities. In addition, fructose significantly increased aortic endothelin and nitric oxide concentrations. Both IFX and TOC attenuated the fructose-induced increase in blood pressure, insulin resistance, and the concentrations of uric acid, MDA and IL-6. TOC significantly reduced fructose-induced increase in triglycerides and cholesterol. In addition, IFX increased plasma SOD and catalase activities. Our results showed that both IFX and TOC were partially successful in reversing fructose – induced changes.

KW - Blood pressure

KW - Fructose

KW - Infliximab

KW - Insulin resistance

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85047533597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047533597&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2018.05.118

DO - 10.1016/j.biopha.2018.05.118

M3 - Article

AN - SCOPUS:85047533597

VL - 105

SP - 182

EP - 186

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -